Associated Papers
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Enhanced computational strategies for categorizing HER2 kinase domain variants of uncertain significance through structural and functional analysis.
Loganathan T et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society, 2025
Precision in prediction: tailoring machine learning models for breast cancer missense variants pathogenicity prediction.
Ahmad RM et al.
Briefings in Bioinformatics, 2025
High-throughput characterization of 5886 HER2 variants identifies 112 new in cellulo gain-of-function mutations.
Giacoletto CJ et al.
Genomics, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Revisiting variation in the somatic mutation landscape of non-small cell lung cancer.
Pathak V et al.
Hgg Advances, 2025
New Gain-of-Function Mutations Prioritize Mechanisms of HER2 Activation.
Giacoletto CJ et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
CDK4 gene copy number increase and concurrent genetic changes in acral melanoma of a Chinese cohort.
Yang L et al.
Pathology, 2025
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).
Hao W et al.
International Journal of Molecular Medicine, 2025
The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population.
Erices JI et al.
Frontiers in Oncology, 2025
Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer.
Corné J et al.
Molecular Oncology, 2024
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients.
Hong L et al.
Npj Precision Oncology, 2024
HER2 mutation as an emerging target in advanced breast cancer.
Bon G et al.
Cancer Science, 2024
Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.
Chen SH et al.
Cancer Medicine, 2024
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.
Gómez Tejeda Zañudo J et al.
Nature Communications, 2024
Response to furmonertinib in a patient with non-small cell lung cancer harboring HER2 exon 21 insertion mutation: a case report.
Ni C et al.
Frontiers in Oncology, 2024
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Jhaveri K et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2023
Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer.
Marín A et al.
Cancer Research, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects.
Ishiyama N et al.
Cancer Research, 2023
Sensitive Detection of Cell-Free Tumour DNA Using Optimised Targeted Sequencing Can Predict Prognosis in Gastro-Oesophageal Cancer.
Wallander K et al.
Cancers, 2023
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review.
Vaghi C et al.
Cancer Treatment Reviews, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.
Grote I et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2022
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.
Kalra R et al.
Cancer Research, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.
Wilding B et al.
Nature Cancer, 2022
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.
LeNoue-Newton ML et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2022
ERBB2 S310F mutation independently activates PI3K/AKT and MAPK pathways through homodimers to contribute gallbladder carcinoma growth.
Fan K et al.
Medical Oncology (northwood, London, England), 2022
Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib.
Shishido SN et al.
Npj Breast Cancer, 2022
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.
Grote I et al.
Cancer Medicine, 2021
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
Hanker AB et al.
Cancer Cell, 2021
The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer.
Gitlitz BJ et al.
Jto Clinical and Research Reports, 2021
Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review.
Qu Y et al.
Oncotargets and Therapy, 2021
Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies.
Zhang C et al.
Clinical and Translational Medicine, 2020
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.
Lang GT et al.
Nature Communications, 2020
Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy.
Schnitzler T et al.
Cellular Oncology (dordrecht, Netherlands), 2020
Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate.
Pandey A et al.
Nature Communications, 2020
ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications.
Jin W
Journal of Clinical Medicine, 2020
Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations.
Harrison BT et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2020
Genomic Landscape and Targeted Treatment of Gallbladder Cancer: Results of a First Ongoing Prospective Study.
Patel A et al.
South Asian Journal of Cancer, 2020